Novel treatments for bipolar disorder
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Treatments other than lithium have recently emerged as equally important in the management of bipolar disorder. The spectrum of efficacy of newer treatments differs from lithium and among the novel drug treatments valproate, generally used as the better tolerated divalproex form, principally benefits manic symptomatology both acutely and in prophylaxis. Atypical antipsychotic drugs have demonstrated efficacy in reducing acute manic symptoms. No controlled evidence of efficacy in prophylaxis has been published. Lamotrigine has demonstrated efficacy in both acute bipolar depression and maintenance efficacy in rapid cycling bipolar patients, especially those patients with bipolar II disorder, which is principally manifested as depression. Randomised, double-blind, placebo- controlled studies provide good evidence that regimens of risperidone or olanzapine in combination with lithium or valproate provide greater improvement in acute mania than the mood stabilisers alone. Similarly, valproate combined with antipsychotics provided greater improvement in mania than antipsychotic medication alone and resulted in lower dosage of the antipsychotic medication. A positive but unclear placebo-controlled study of omega-3 fatty acids added to lithium in bipolar disorder needs confirmation in standard clinical trial paradigms. Several other drugs that were reported as beneficial in various facets of bipolar disorder in open trials have not differed from placebo when studied in randomised, placebo-controlled trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Calabrese, J. R., Bowden, C. L., Sachs, G. S., Ascher, J. A., Monaghan, E., Rudd, G. D., & The Lamictal 602 Study Group (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0203 · Cited by 1,054
Self-citationThe National Depressive and Manic-depressive Association (DMDA) survey of bipolar members
Lish, J. D., Dime-Meenan, S., Whybrow, P. C., Price, R. A., & Hirschfeld, R. M. A. (1994) · Journal of Affective Disorders · doi:10.1016/0165-0327(94)90104-x · Cited by 897
Omega 3 Fatty Acids in Bipolar Disorder: A Preliminary Double-blind, Placebo-Controlled Trial
Stoll, A. L., Severus, W. E., Freeman, M. P., Rueter, S., Zboyan, H. A., Diamond, E., Cress, K. K., & Marangell, L. B. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.5.407 · Cited by 814
Relapse and impairment in bipolar disorder
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.11.1635 · Cited by 762
Bowden, C. L. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.5.481 · Cited by 678
Self-citationOlanzapine versus placebo in the treatment of acute mania
Tohen, M., Sanger, T. M., McElroy, S. L., Tollefson, G. D., Chengappa, K. N. R., Daniel, D. G., Petty, F., Centorrino, F., Wang, R., Grundy, S. L., et al. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.5.702 · Cited by 585
A Placebo-Controlled Study of Lamotrigine and Gabapentin Monotherapy in Refractory Mood Disorders
Frye, M. A., Ketter, T. A., Kimbrell, T. A., Dunn, R. T., Speer, A. M., Osuch, E. A., Luckenbaugh, D. A., Corá-Locatelli, G., Leverich, G. S., & Post, R. M. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200012000-00004 · Cited by 446
Course of the Manic-Depressive Cycle and Changes Caused by Treatments
Kukopulos, A., Reginaldi, D., Laddomada, P., Floris, G., Serra, G., & Tondo, L. (2008) · Pharmacopsychiatry · doi:10.1055/s-2007-1019628 · Cited by 436
Suppes, T., Webb, A., Paul, B., Carmody, T., Kraemer, H., & Rush, A. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.8.1164 · Cited by 238
Differential Response to Lithium and Carbamazepine in the Prophylaxis of Bipolar Disorder
Greil, W., Kleindienst Nikolaus, D.-S., Erazo Natalia, D.-P., & Muller-Oerlinghausen, B. (1998) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199812000-00007 · Cited by 206
Prediction of outcome in mania by mood-congruent or mood-incongruent psychotic features
(1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.11.1580 · Cited by 120
Dr. Egeland and Dr. Hostetter Reply
EGELAND, J. A., & HOSTETTER, A. M. (1983) · American Journal of Psychiatry · doi:10.1176/ajp.140.9.1264 · Cited by 81
Verapamil for the Treatment of Acute Mania: A Double-Blind, Placebo-Controlled Trial
Janicak, P. G., Sharma, R. P., Pandey, G., & Davis, J. M. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.7.972 · Cited by 69
Cited by
Practice Guideline for the Treatment of Patients With Bipolar Disorder (Revision)
Hirschfeld, R. M. A., Bowden, C. L., Gitlin, M. J., Keck, P. E., Perlis, R. H., Suppes, T., Thase, M. E., & Wagner, K. D. (2003) · Focus · doi:10.1176/foc.1.1.64 · Cited by 585
Self-citationBelmaker, R. H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra035354 · Cited by 473
Beyond Monoamines: Glutamatergic Function in Mood Disorders
Kugaya, A., & Sanacora, G. (2005) · CNS Spectrums · doi:10.1017/s1092852900010403 · Cited by 290
Polytherapy in Bipolar Disorder
Lin, D., Mok, H., & Yatham, L. N. (2006) · CNS Drugs · doi:10.2165/00023210-200620010-00003 · Cited by 91
Australian and New Zealand clinical practice guidelines for the treatment of bipolar disorder
Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Bipolar Disorder (2004) · Australian and New Zealand Journal of Psychiatry · doi:10.1111/j.1440-1614.2004.01356.x · Cited by 90
Metadata
- Authors
- Bowden, C. L.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2001-04
- Volume
- 10
- Issue
- 4
- Pages
- 661-671
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2124531204
- Cited by
- 36
- References
- 13
- FWCI
- 3.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.